Insider Analysis: Kantar Health On Optimizing Indian Cancer Patient Assistance Programs For Maximum Impact
This article was originally published in PharmAsia News
Executive Summary
With a rapidly rising cancer burden but the high costs of new targeted therapies remaining out of reach for many, India has seen the increasing adoption of company-backed patient assistance programs, or PAPs, to support access to effective treatments. But what is the best approach? Kantar Health’s Gauri Pathak and Neesha Suvarna look at the issues.